Relief of symptoms pharmacological

Cannabis and cannabinoids for symptomatic treatment for people with multiple sclerosis

Abstract Background Spasticity and chronic neuropathic pain are common and serious symptoms in people with multiple sclerosis (MS). These symptoms increase with disease progression and lead to worsening disability, impaired activities of daily living and quality of life. Anti‐spasticity medications and analgesics are of limited benefit or poorly tolerated. Cannabinoids may reduce spasticity and pain […]

Share

Pharmacological treatment for memory disorder in multiple sclerosis

Abstract Background This is an update of the Cochrane review “Pharmacologic treatment for memory disorder in multiple sclerosis” (first published in The Cochrane Library 2011, Issue 10). Multiple sclerosis (MS) is a chronic immune-mediated, inflammatory, demyelinating, neurodegenerative disorder of the central nervous system (CNS) and can cause both neurological and neuropsychological disability. Both demyelination and […]

Share

Carnitine for fatigue in multiple sclerosis

Abstract Background Fatigue is reported to occur in up to 92% of patients with multiple sclerosis (MS) and has been described as the most debilitating of all MS symptoms by 28% to 40% of MS patients. Objectives To assess whether carnitine (enteral or intravenous) supplementation can improve the quality of life and reduce the symptoms […]

Share

Sildenafil citrate for erectile dysfunction in patients with multiple sclerosis

Abstract Background Erectile dysfunction (ED) is a common sexual disease in male patients with multiple sclerosis (MS). Sildenafil citrate is considered as an effective drug in the treatment of male ED in the general population, but it has not been systematically reviewed in patients with MS. Objectives To assess the efficacy and safety of sildenafil […]

Share

Anti-spasticity agents for multiple sclerosis

Abstract Background Spasticity is a common problem in multiple sclerosis (MS) patients causing pain, spasms, loss of function and difficulties in nursing care. A variety of oral and parenteral medications are available. Objectives To assess the absolute and comparative efficacy and tolerability of anti-spasticity agents in MS patients. Search methods We searched the Cochrane MS […]

Share
  • The review abstracts published on this site are the property of John Wiley & Sons, Ltd., and of the Cochrane Review Groups that have produced the reviews.
Share
Share